Chemo-Pharma Laboratories Ltd.
Snapshot View

37.70 +1.75 ▲4.9%

07 February 2023, 04:01:00 PM
Volume: 506

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.thechemopharmalaboratoriesltd.com
Market Cap 5.66 Cr.
Enterprise Value(EV) 0.07 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 2.23 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 16.88 Trailing Twelve Months Ending 2022-12
Industry PE 32.80 Trailing Twelve Months Ending 2022-12
Book Value / Share 78.33 Trailing Twelve Months Ending 2022-12
Price to Book Value 0.48 Calculated using Price: 37.70
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 0.15 Cr. 1,500,000 Shares
FaceValue 10
Company Profile
Chemo Pharma Laboratories has been an established company since 1942 and has been making pharmaceuticals and also had diversified into bulk drugs. However, due to increase in competition and flow of new drugs, the company had to dispose the business and pay all its liabilities and dues.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+4.87%
1 Week
-3.33%
1 Month
+3.01%
3 Month
-1.95%
6 Month
-0.79%
1 Year
-14.32%
2 Year
+41.20%
5 Year
-13.33%
10 Year
+93.83%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 5.10 5.61 4.15 60.99 1.00 2.02 3.94 2.30 4.97
Return on Capital Employed (%) 6.22 7.52 5.96 68.41 7.54 2.50 4.69 2.86 3.24
Return on Assets (%) 4.79 5.20 3.90 57.64 0.96 2.00 3.88 2.27 4.99

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 5 5 5 10 10 10 11 11 12 12
Non Curr. Liab. 0 0 0 0 0 0
Curr. Liab. 0 0 0 1 0 0 0 0 0 0
Minority Int.
Equity & Liab. 5 6 6 11 10 10 11 11 11 11
Non Curr. Assets 4 3 3 2 2 2 2 0 5 6
Curr. Assets 2 2 2 9 9 9 9 11 6 6
Misc. Exp. not W/O
Total Assets 5 6 6 11 10 10 11 11 11 11

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales
Other Income 0 1 0 6 1 1 1 1 1 1
Total Income 0 1 0 6 1 1 1 1 1 1
Total Expenditure 0 0 0 0 0 -1 0 0 0 0
PBIDT 0 0 0 5 1 0 1 0 0 0
Interest
Depreciation 0 0 0 0
Taxation 0 0 0 -1 -1 0 0 0 0 0
Exceptional Items
PAT 0 0 0 5 0 0 0 0 1 0
Adjusted EPS 2 2 1 31 1 1 3 2 4 2

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 6 -2 -5 5 0 0
Cash Fr. Inv. 0 0 0 0 1 1 1 1 0 1
Cash Fr. Finan. -1 1 2 -2
Net Change 0 0 0 0 6 1 -5 6 1 -1
Cash & Cash Eqvt 0 0 0 0 7 8 3 9 2 1

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 27.89 27.89 27.89 27.89 27.89 27.89 27.89 27.89 27.89
Public 72.11 72.11 72.11 72.11 72.11 72.11 72.11 72.11 72.11
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Wed, 01 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed copies of the newspaper advertisement pertaining to financial results of the Company for the quarter and nine months ended December 31 2022.
Tue, 31 Jan 2023
Outcome Of Board Meeting Held On Tuesday January 31 2023
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that the Board of Directors of the Company at their meeting held today i.e. January 31 2023 approved the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31
2022 along with the Limited Review Report thereon.
Tue, 31 Jan 2023
Board Meeting Outcome for Un-Audited Financial Results Held On Tuesday January 31 2023
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that the Board of Directors of the Company at their meeting held today i.e. January 31 2023 approved the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31 2022 along with the Limited Review Report thereon.

Technical Scans View Details >>

Tue, 07 Feb 2023
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Opening at High Opening at High
Closing Above Previous High Closing Above Previous High

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 241,289.12 1,005.65 -1.7%
Cipla Ltd. 83,256.90 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. 73,968.14 4,441.90 +2.1%
Divi's Laboratories Ltd. 72,982.62 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. 62,135.10 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. 51,898.92 1,533.45 -0.4%
Zydus Lifesciences Ltd. 48,525.07 479.40 +2.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 57.29 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-12 31.56 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.30 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-12 30.45 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 74.00 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.45 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-12 23.54 479.40 +2.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.36 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-12 3.67 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.36 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-12 5.87 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.38 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.14 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.81 479.40 +2.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 0.04 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 479.40 +2.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 13.10 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 479.40 +2.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 13.10 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 479.40 +2.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 479.40 +2.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 479.40 +2.0%

FAQ's On Chemo-Pharma Laboratories Ltd.

What is Chemo Pharma Labs share price?

Can I buy Chemo Pharma Labs shares now?

What is the Market Cap of Chemo Pharma Labs?

What are the key metrics to analyse Chemo Pharma Labs?

What is the 52 Week High and Low of Chemo Pharma Labs?

What is the trend of Chemo Pharma Labs share price?